|
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for …
Sacramento Bee SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product … Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid … Leerink Swann Starts Rigel Pharmaceuticals (RIGL) at Outperform; Top Biotech … |
View full post on asthma – Google News